Atlas FDA

PartoSure test

FDA premarket approval P160052 · decided 2018-04-11

Approval details

PMA number
P160052
Trade name
PartoSure test
Generic name
Placental alpha microglobulin-1 immunoassay
Applicant
Qiagen, Inc.
Date received
2016-11-30
Decision date
2018-04-11
Days to decision
497 days
Decision code
APPR
Product code
QBB
Advisory committee
Clinical Toxicology
Expedited review
No
Location
Germantown, MD
Statement
Approval for the PartoSure test. The device is a rapid, qualitative test for detecting the presence of placental alpha microglobulin 1 (PAMG-1) in cervicovaginal secretions. The device is indicated as an aid to rapidly assess the risk of spontaneous preterm delivery in <= 7 days from the time of cervicovaginal sample collection in pregnant women with signs and symptoms of early preterm labor, intact amniotic membranes and minimal cervical dilatation (<3 cm), sampled between 24 weeks, 0 days and

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
ipsogen JAK2 RGQ PCR Kit (K172287)Qiagen, Inc.2018-01-12
ipsogen JAK2 RGQ PCR Kit (DEN160028)Qiagen, Inc.2017-03-27